Atlas Trials

The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy

Clinical trial NCT04670107 · COMPLETED

Trial details

NCT number
NCT04670107
Sponsor
The Affiliated Hospital of Qingdao University
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
NSCLCAngiogenesisImmunotherapy
Start date
2018-06-01
Primary completion
2020-10-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.